After yesterday's closing bell, the Pleasanton, CA-based medical device company reported adjusted earnings of $1.83 per share, topping analysts' estimates of $1.58 per share.
Revenue increased by 1% to $449.6 million year-over-year and surpassed Wall Street's expectations of $411.9 million.
For fiscal 2016, Cooper expects earnings per share between $8 and $8.30 on revenue of $1.87 billion to $1.9 billion, higher than analysts' forecasts. Analysts are looking for earnings of $7.77 per share on revenue of $1.86 billion.
About 1.18 million of the company's shares changed hands by this afternoon compared to its average volume of 505,665 shares per day.
Separately, TheStreet Ratings Team has a "Hold" rating with a score of C+ on the stock.
The primary factors that have impacted the rating are mixed - some indicating strength, some showing weaknesses, with little evidence to justify the expectation of either a positive or negative performance for this stock relative to most other stocks.
The company's strengths can be seen in multiple areas, such as its increase in net income, reasonable valuation levels and expanding profit margins.
As a counter to these strengths, the team also finds weaknesses including disappointing return on equity, weak operating cash flow and a generally disappointing performance in the stock itself.
Recently, TheStreet Ratings objectively rated this stock according to its "risk-adjusted" total return prospect over a 12-month investment horizon. Not based on the news in any given day, the rating may differ from Jim Cramer's view or that of this articles's author.
You can view the full analysis from the report here: COO